• Promising Clinical Performance of Pretargeted Immuno-PET with Anti-CEA Bispecific Antibody and Gallium-68-Labelled IMP-288 Peptide for Imaging Colorectal Cancer Metastases: A Pilot Study, Touchefeu, Y.; Bailly, C.; Frampas, E.; Eugène, T.; Rousseau, C.; Bourgeois, M.; Bossard, C.; Faivre-Chauvet, A.; Rauscher, A.; Masson, D.; David, A.; Cerato, E.; Carlier, T.; Sharkey, R. M.; Goldenberg, D. M.; Barbet, J.; Kraeber-Bodere, F.; Bodet-Milin, C., Eur J Nucl Med Mol Imaging 2021, 48 (3), 874–882. doi:10.1007/s00259-020-04989-3

  • Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the IPET-MTC Study, Bodet-Milin, C.; Faivre-Chauvet, A.; Carlier, T.; Ansquer, C.; Rauscher, A.; Frampas, E.; Toulgoat, F.; Masson, D.; Bourgeois, M.; Cerato, E.; Rohmer, V.; Couturier, O.; Drui, D.; Goldenberg, D. M.; Sharkey, R. M.; Barbet, J.; Kraeber-Bodere, F., J Nucl Med 2021, 62 (9), 1221–1227. doi:10.2967/jnumed.120.252791

  •  Copper-64-Labeled 1C1m-Fc, a New Tool for TEM-1 PET Imaging and Prediction of Lutetium-177-Labeled 1C1m-Fc Therapy Efficacy and Safety, Delage JA, Gnesin S, Prior JO, Barbet J, Le Saëc P, Marionneau-Lambot S, Gouard S, Chérel M, Bourgeois M, Schaefer N, Viertl D, Fierle JK, Dunn SM, Faivre-Chauvet A. Cancers (Basel). 2021 Nov 25;13(23):5936.
    doi:10.3390/cancers13235936

  • Impact of DOTA Conjugation on Pharmacokinetics and Immunoreactivity of [177Lu]Lu-1C1m-Fc, an Anti TEM-1 Fusion Protein Antibody in a TEM-1 Positive Tumor Mouse Model, Delage JA, Faivre-Chauvet A, Barbet J, Fierle JK, Schaefer N, Coukos G, Viertl D, Dunn SM, Gnesin S, Prior JO, Pharmaceutics, 2021 Jan 13;13(1):96. doi: 10.3390/pharmaceutics13010096

  • Cell Tracking in Cancer Immunotherapy, Perrin J, Capitao M, Mougin-Degraef M, Guérard F, Faivre-Chauvet A, Rbah-Vidal L, et al, Front Med. 14 févr 2020;7:34. https://doi.org/10.3389/fmed.2020.00034

  • Targeting Stereotactic Body Radiotherapy on Metabolic PET- and Immuno-PET-Positive Vertebral Metastases, Pichon B, Rousseau C, Blanc-Lapierre A, Delpon G, Ferrer L, Libois V, et al, Biomedicines. 28 nov 2020;8(12):548. https://doi.org/10.3390/biomedicines8120548

  • Targeted-Alpha-Therapy Combining Astatine-211 and anti-CD138 Antibody in a Preclinical Syngeneic Mouse Model of Multiple Myeloma Minimal Residual Disease, Gouard S, Maurel C, Marionneau-Lambot S, Dansette D, Bailly C, Guérard F, et al, Cancers. 22 sept 2020;12(9):2721. https://doi.org/10.3390/cancers12092721

  • Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project, Bailly C, Carlier T, Berriolo-Riedinger A, Casasnovas O, Gyan E, Meignan M, et al, Haematologica. janv 2020;105(1):e33‑6. https://doi.org/10.3324/haematol.2019.223016

  • Prognostic Impact of Pretherapeutic FDG-PET in Localized Anal Cancer, Le Thiec M, Testard A, Ferrer L, Guillerminet C, Morel O, Maucherat B, et al, Cancers. 9 juin 2020;12(6):1512. https://doi.org/10.3390/cancers12061512

  • ImmunoPET in Multiple Myeloma—What? So What? Now What?, Bailly C, Chalopin B, Gouard S, Carlier T, Remaud-Le Saëc P, Marionneau-Lambot S, et al, Cancers. 4 juin 2020;12(6):1467. https://doi.org/10.3390/cancers12061467